OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$1.36
Market Cap
$461.19M
52W High
$1.69
52W Low
$1.16
ADV30
4,300,448
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,488,000 | — | -16,444,000 | -24,877,000 | 124,206,000 | 100,051,000 | 140,762,000 |
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
| Sep 2025 | 1,752,000 | — | -17,625,000 | -20,051,000 | 57,596,000 | 32,565,000 | 54,063,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,869,000
Investing CF
$-148,000
Financing CF
$133,864,000
CapEx
$-153,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-452,121,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-73,369,000
Pretax Income TTM
$-81,811,000
Interest Exp TTM
$8,442,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,581,000
EBITDA
$-67,173,000
Free Cash Flow
$-1,974,375
Enterprise Value
$449,125,152
Total Cash
$100,051,000
Total Debt
$87,986,000
Shares Out
339,110,401
Trailing EPS
$-0.26
Book Value
$-0.05
ROE
-660.0%
ROA
-48.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | — | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | — | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | — | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | — | -60,079,000 |
TTM Snapshot
Revenues TTM
$1,136,000
NetIncome TTM
$-12,970,000
OpCashFlow TTM
$0
Assets (Latest)
$82,442,000
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | $460.74M | $3.00 | — |
| CMPX | Compass Therapeutics, Inc. | $432.21M | $2.40 | — |
| CCCC | C4 Therapeutics, Inc. | $504.40M | $4.10 | — |
| KYTX | Kyverna Therapeutics, Inc. | $509.59M | $8.24 | — |
| CABA | Cabaletta Bio, Inc. | $525.59M | $3.10 | — |
News headlines (Yahoo Finance, 1h cache)
Ocugen to Participate in Upcoming September Investor and Industry Conferences
2026-08-25 11:02 · Yahoo
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
2026-08-16 01:01 · Yahoo
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
2026-08-13 18:14 · Yahoo
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
2026-08-07 17:18 · Yahoo
Ocugen Q2 Earnings Call Highlights
2026-08-07 06:04 · Yahoo
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...
2026-08-06 23:15 · Yahoo
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
2026-07-11 00:02 · Yahoo
Ocugen to Participate in Upcoming July Industry Conferences
2026-07-01 11:00 · Yahoo
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance
2026-06-06 01:05 · Yahoo
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.